Stockscreener 앱 받기
6.21
0.48%
-0.03
전일 마감가:
$6.24
열려 있는:
$6.29
하루 거래량:
1.56M
Relative Volume:
0.74
시가총액:
$799.19M
수익:
$628.25M
순이익/손실:
$-78.55M
주가수익비율:
-10.02
EPS:
-0.62
순현금흐름:
$-29.73M
1주 성능:
-13.51%
1개월 성능:
-11.29%
6개월 성능:
-56.21%
1년 성능:
-57.20%
1일 변동 폭
$6.20
$6.355
1주일 범위
$6.20
$7.24
52주 변동 폭
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
NEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
6.21 | 924.03M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
404.94 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
188.07 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.87 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.04 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.96 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-15 | 개시 | Guggenheim | Neutral |
| 2025-04-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 개시 | Jefferies | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
What drives NeoGenomics Inc. stock priceUnmatched profit growth - Autocar Professional
What analysts say about NeoGenomics Inc. stockUnmatched profit potential - Autocar Professional
NeoGenomics Inc. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
Is NeoGenomics Inc. a good long term investmentBreakthrough wealth creation - Jammu Links News
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy - Nature
Neogenomics Shares Plunge 7.14% Amid Earnings Woes - AInvest
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
Pathological Examination Market Gaining Momentum in Cancer - openPR.com
NeoGenomics (NASDAQ:NEO investor five-year losses grow to 81% as the stock sheds US$71m this past week - simplywall.st
Why NeoGenomics Inc. stock attracts strong analyst attention200 Percent Profit Outlook - beatles.ru
Q1 Earnings Highlights: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Testing & Diagnostics Services Stocks - Yahoo Finance
NEO Stock Price and Chart — NASDAQ:NEO - TradingView
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know - Yahoo Finance
NeoGenomics Announces Grand Opening of New Pharma Services Laboratory in Singapore - ACCESS Newswire
Press Release: NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 - 富途牛牛
NeoGenomics (NEO): A Contrarian Play on Turnaround and Undervaluation - AInvest
The past five years for NeoGenomics (NASDAQ:NEO) investors has not been profitable - Yahoo Finance
NeoGenomics Announces Chief Executive Officer Appointment - ACCESS Newswire
Here’s Why NeoGenomics (NEO) Sold Off in Q1 - Insider Monkey
NeoGenomics To Participate In Fireside Chat At Stephens 21st Annual Investment Conference - ACCESS Newswire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 - Bluefield Daily Telegraph
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care - The Joplin Globe
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - Yahoo Finance
NeoGenomics' Market Cap Drops To US$954m Leaving Insiders With Losses - simplywall.st
NeoGenomics Requests to Dismiss Class Action Filed by Investors - TradingView
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021 - ACCESS Newswire
Investor Calendar Invites You to the NeoGenomics Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Tuesday March 1, 2016 - ACCESS Newswire
NeoGenomics at William Blair Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
NeoGenomics at William Blair Conference: Strategic Growth and Innovation - Investing.com Australia
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
Cancer Tumor Profiling Market Rises with Demand - openPR.com
Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com
Fort Myers-based NeoGenomics to unveil new cancer diagnostics at ASCO 2025 - Gulfshore Business
NeoGenomics unveils new oncology diagnostics at ASCO 2025 By Investing.com - Investing.com South Africa
Neogenomics director Kelly buys $38,000 in common stock - Investing.com Australia
Neogenomics director Kelly buys $38,000 in common stock By Investing.com - Investing.com Nigeria
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025 - BioSpace
NeoGenomics unveils new oncology diagnostics at ASCO 2025 - Investing.com
NeoGenomics Approves Key Proposals at Annual Meeting - TipRanks
D. E. Shaw & Co. Inc. Trims Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.04%
1.25%
자본화:
|
볼륨(24시간):